AWM
RDHL

Atticus Wealth Management’s Redhill Biopharma RDHL Stock Holding History

Atticus Wealth Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$246 – 611
2023
Q1 		$246 Hold
2
– – ﹤0.01% 524
2022
Q4 		$340 Hold
2
– – ﹤0.01% 509
2022
Q3 		$2K Hold
2
– – ﹤0.01% 508
2022
Q2 		$2K Hold
2
– – ﹤0.01% 541
2022
Q1 		$6K Sell
2
-2
-50% -$4.74K ﹤0.01% 452
2021
Q4 		$11K Buy
+4
New +$16K ﹤0.01% 355

Other funds holding RDHL

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atticus Wealth Management's RDHL Position: Q2 2023 in Review

Atticus Wealth Management sold out of Redhill Biopharma (RDHL) in Q2 2023, closing a stake of 2 shares — an estimated $246 sold.

Atticus Wealth Management first reported a position in RDHL in Q4 2021 and held it in 6 quarters. The position peaked at $11K in Q4 2021. 18 funds tracked by Wall St. Rank hold RDHL as of Q2 2023.

  • Atticus Wealth Management reported no remaining Redhill Biopharma position as of Q2 2023 after selling out during the quarter.
  • Atticus Wealth Management sold 2 Redhill Biopharma shares in Q2 2023, an estimated $246.
  • Atticus Wealth Management first reported a position in Redhill Biopharma in Q4 2021 and held it in 6 quarters.
  • Atticus Wealth Management's Redhill Biopharma position peaked at $11K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2023.

Based on Atticus Wealth Management's 13F filing for Q2 2023, filed 21 Jul 2023.